menu
    • menu
    [{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Bisantrene","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"FTO protein","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Race Oncology Limited","highestDevelopmentStatusID":"9","companyTruncated":"City of Hope \/ Race Oncology Limited"}]

    Find Clinical Drug Pipeline Developments & Deals for Bisantrene

    Menu

    Bisantrene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Ardena

    Belgium arrow
    ICHH-25
    Not Confirmed

    Ardena

    Belgium arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bisantrene

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Race Oncology

    Deal Size : $1.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220

    Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

    Product Name : RC220

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    July 12, 2023

    Lead Product(s) : Bisantrene

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Race Oncology

    Deal Size : $1.0 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    City of Hope

    U.S.A arrow
    ICHH-25
    Not Confirmed

    City of Hope

    U.S.A arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bisantrene

    Therapeutic Area : Oncology

    Study Phase : Phase II/ Phase III

    Sponsor : Race Oncology Limited

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Race Executes Global License Agreement with City of Hope to Access FTO IP

    Details : Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    July 10, 2023

    Lead Product(s) : Bisantrene

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Sponsor : Race Oncology Limited

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth